A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag.

ABSTRACT: Avatrombopag is a next-generation thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo surgery and thrombocytopenia in patients with chronic immune thrombocytopenia. However, realistic data on its post-marketing long-term safety and tolerability in large sample populations are incomplete. The adverse event (AE) reports of avatrombopag were analyzed based on the FAERS database. By extracting large-scale data from the FAERS database, this study used various signal quantification techniques such as reporting odds ratios, proportional reporting ratios, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker to calculate and evaluate the ratio and association between avatrombopag

SUBMITTER: Xue Z 

PROVIDER: S-EPMC11574250 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature